April 27/Amsterdam/Bloomberg -- Royal DSM NV said it is capable of pursuing other potential acquisitions even as it works to integrate its $1.09 billion purchase of Martek Biosciences Corp.
There will be “no pause” in the takeover strategy with other targets like Martek out there, chief financial officer Rolf-Dieter Schwalb said on a call. First-quarter earnings beat estimates, sending DSM shares up the most in two years.